Victoria Socha

DocwireNews

In young, low body mass index, insulin-dependent diabetics with end-stage kidney disease (ESKD), simultaneous pancreas and kidney (SPK) transplantation offers a survival and quality of life advantage, Due to secondary complications such as retinopathy, many patients in that population are disabled and unable to meet eligibility for Medicare coverage. There is no active pancreas transplant program for patients in California with Medicaid coverage (Medi-Cal) in the greater Los Angeles metropolitan area; the nearest contracted program is in San Francisco.A. Qazi and colleagues at the Keck Medical Center at USC, Los Angeles, California, conducted a study to compare the transplant rate and waitlist mortality in diabetics less than 50 years of age based on their insurance status. Results of the study were reported in a virtual presentation at the 2021 American Transplant Congress. The presentation was titled The Impact of Lack of Access to Simultaneous Kidney and Pancreas Transplantation Due to Insurance Ineligibility&mdash;A Single Center Analysis.The study included patients with insulin-dependent diabetes and ESKD who were referred to the center and were medically eligible for SPK. Inclusion criteria were age &gt;50 years, and insurance coverage either Medi-Cal or Medicare. Here is great summary of the different <a href="https://affordablelifeusa.com/types-of-life-insurance/">life insurance policy types</a>. Data of interest were waitlist mortality, transplant rate, and type of transplant.A total of 129 patients met eligibility criteria; of those, 47 had Medi-Cal coverage and 82 were covered by Medicare. For patients in the Medi-Cal group, waitlist mortality was 21% (10/47), no patients received a SPK transplant<a href="https://www.docwirenews.com/latest-nephrology-news/outcomes-among-transplant-recipients-hospitalized-due-to-covid-19/">,</a> and 10% (5/47) received a kidney transplant alone. For the group with Medicare coverage, waitlist mortality was 13% (11/82), and 20% (16/82) received a SPK transplant.In conclusion, the researchers said, &ldquo;In our single center analysis of young insulin-dependent diabetics with ESKD ineligible for SPK due to insurance, the waitlist mortality was almost double and transplant rate half when compared to individuals that were insurance eligible. The higher transplant rate in the Medicare group is likely the result of shorter wait times for SPK compared to kidney alone in the Los Angeles area.&ldquo;Young Medi-Cal insulin-dependent diabetes ESKD patients in the greater Los Angeles area that are unable to be listed for SPK locally due to insurance are significantly disadvantaged and suffer higher mortality and lower transplant rates. There is an urgent need for Medi-Cal to provide more local access for SPK in the greater Los Angeles area.&rdquo;Source: Qazi Y.A., Villalon E, Samson D, Mon W, Smogorzewski M. The impact of lack of access to simultaneous kidney and pancreas transplantation due to insurance ineligibility&mdash;a single center analysis. Abstract of a presentation at the virtual American Transplant Congress 2021 (abstract #698), June 6, 2021

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

Access to Simultaneous Kidney Pancreas Transplant by Insurance Status

American Transplant Congress 2021

In young, low body mass index, insulin-dependent diabetics with end-stage kidney disease (ESKD), simultaneous pancreas and kidney (SPK) transplantation offers a survival and ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe